Who are City Therapeutics's main competitors?

Named competitors: Alnylam Pharmaceuticals (ALNY), Arrowhead Pharmaceuticals (ARWR), Ionis Pharmaceuticals (IONS), Regeneron (REGN), Bristol Myers Squibb (BMY). The cockpit's measured peer set (industry) also includes Hunan Warrant Pharmaceutical (688799.SS), Northeast Pharmaceutical (000597.SZ), Immatics (IMTX), Nxera Pharma (4565.T), GuangYuYuan Chinese Herbal Medicine (600771.SS), Dezhan Healthcare (000813.SZ).

← CockpitCompetitor Analysis › CTY City Therapeutics, Inc.Open in the cockpit ↗

City Therapeutics, Inc.CTYCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Clinical-stage biotech developing RNAi medicines, led by anticoagulant CITY-FXI (Factor XI) plus eye-disease and anemia programs.

≈ A smaller, earlier-stage Alnylam

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$944M

US dollars, full cap

Free float

60%

of shares outstanding

$/day

$6.99M

20-day average traded

Fwd P/E

n/m

no positive forecast

ROIC−WACC

n/a

WACC 8.9%

Hurdle

n/a

no reverse DCF

Close · USD$18.25

1D+6.9%

1W-11.9%

1Mn/a

3Mn/a

6Mn/a

YTDn/a

1Yn/a

ATR %13.0%

52w lowhigh23.6% off high

What City Therapeutics does

Clinical-stage biotech developing RNAi medicines, led by anticoagulant CITY-FXI (Factor XI) plus eye-disease and anemia programs.

Pre-revenue: funds early-stage trials from investor capital, including its October 2026 Nasdaq IPO. RNAi medicines switch off a gene's messenger RNA to cut production of a harmful protein, and the lead drug targets Factor XI, a clotting protein, as an anticoagulant. Co-founder John Maraganore, former Alnylam CEO, is executive chair; Bausch + Lomb and Biogen are research partners.

In one line: A smaller, earlier-stage Alnylam.

Products and services

CITY-FXI (Factor XI anticoagulant)
CITY-RBP4 (Stargardt disease, geographic atrophy)
CITY-TFR2 (anemia of chronic disease)

Customers

Patients needing anticoagulation
Patients with eye disease
Patients with anemia of chronic disease

Where it sits in the supply chain

Biotechnology
Clinical-stage drug developer
RNA interference (RNAi) therapeutics

What could go right

Research partners Bausch + Lomb and Biogen
Factor XI anticoagulant Phase 1 safety data

What could go wrong

Early stage with no approved product
Crowded Factor XI field with large pharma rivals

Moat: narrow (IP / patents, process know-how). Proprietary RNAi trigger designs and delivery conjugates; founders have RNAi drug-development experience.

Headquarters: Massachusetts, United States · Founded: 2023

Named competitors

City Therapeutics at a glance

Size City Therapeutics (CTY) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $944M, the 2287th largest of 3,117 United States companies the cockpit tracks. Shares closed at $18.25 on 6 Nov 2026.

Growth Revenue grew 388.2% over the last twelve months (peer median -0.6%); the operating margin is -441.8% (peer median 4.5%).

City Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024
Revenue	n/a	$13.6M	$2.78M
Revenue growth	—	+388%	—
Gross profit	n/a	$12.4M	$2.35M
EBITDA	n/a	-$58.8M	-$28.7M
Net income	n/a	-$58.5M	-$27.8M
Free cash flow	n/a	-$44.0M	-$23.9M
Capital expenditure	n/a	$2.40M	$3.54M
Total debt	n/a	$212M	$167M

Quarterly statements and history in the cockpit →

City Therapeutics competitors and peer comparison

Head to head with its named competitors (CTY vs ALNY vs ARWR vs IONS)
Company	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g
City Therapeutics CTY	$944M	n/a	+388%	-442%	n/a	n/a
Alnylam Pharmaceuticals ALNY	$20.9B	-47%	+56%	20%	4.0×	0.9%
Arrowhead Pharmaceuticals ARWR	$8.22B	-20%	+17%	-34%	11.9×	n/a
Ionis Pharmaceuticals IONS	$6.55B	-48%	-7%	-68%	7.7×	n/a
Regeneron Pharmaceuticals REGN	$93.5B	+27%	+19%	30%	5.2×	-2.2%
Bristol Myers Squibb BMY	$127B	+12%	+4%	33%	3.2×	-12.9%

How City Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

City Therapeutics against its 20 peers (data as of 6 Nov 2026)
Measure	CTY	Peer median	Rank in peer set
Distance from 52-week high	-23.6%	-32.5%	5th highest of 21
Revenue growth (TTM)	+388.2%	-0.6%	highest of 18
Operating margin	-441.8%	4.5%	2nd lowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g	Delivered g
City Therapeutics CTY	United States	$944M	n/a	+388%	-442%	n/a	n/a	n/a
Hunan Warrant Pharmaceutical 688799.SS	China	$942M	-20%	+5%	9%	4.7×	n/a	n/a
Northeast Pharmaceutical 000597.SZ	China	$948M	-10%	-6%	3%	1.0×	-6.8%	-0.7%
Immatics IMTX	United States	$952M	-44%	-65%	-556%	10.7×	n/a	n/a
Nxera Pharma 4565.T	Japan	$932M	+63%	+24%	14%	5.1×	16.2%	+27.3%
GuangYuYuan Chinese Herbal Medicine 600771.SS	China	$930M	-24%	-6%	5%	4.4×	33.2%	+4.2%
Dezhan Healthcare 000813.SZ	China	$928M	-18%	-10%	-121%	15.8×	n/a	n/a
Procter & Gamble Health PGHL.NS	India	$971M	+4%	+13%	31%	6.3×	5.5%	+9.3%
Kissei Pharmaceutical 4547.T	Japan	$973M	-16%	+6%	6%	1.1×	n/a	n/a
Strides Pharma Science STAR.NS	India	$973M	-13%	+11%	14%	2.1×	18.1%	+7.8%
Jiangsu Yahong Meditech 688176.SS	China	$973M	-12%	+15%	-172%	17.8×	n/a	n/a
Oric Pharmaceuticals ORIC	United States	$914M	0%	n/a	n/a	n/a	n/a	n/a
Bide Pharmatech 688073.SS	China	$912M	+5%	+10%	19%	3.6×	16.7%	+27.7%
Hunan Er-Kang Pharmaceutical 300267.SZ	China	$909M	-33%	-14%	-29%	5.2×	n/a	n/a
Wanbangde Pharmaceutical 002082.SZ	China	$909M	-65%	-11%	-3%	5.9×	-1.2%	-39.5%
MoonLake Immunotherapeutics MLTX	United States	$981M	-32%	n/a	n/a	n/a	n/a	n/a
Guizhou Bailing Group Pharmaceutical 002424.SZ	China	$907M	-12%	-25%	2%	2.9×	16.2%	-0.2%
Zhejiang Garden Biopharmaceutical 300401.SZ	China	$983M	-7%	+2%	24%	5.5×	10.2%	+13.4%
SSY 2005.HK	Hong Kong	$990M	+10%	-4%	12%	2.3×	2.1%	-0.5%
Savara SVRA	United States	$992M	-8%	n/a	n/a	n/a	n/a	n/a
Beijing Sun-Novo Pharmaceutical Research 688621.SS	China	$894M	-8%	-1%	-2%	6.1×	n/a	n/a

Questions

Who are City Therapeutics's main competitors?: Named competitors: Alnylam Pharmaceuticals (ALNY), Arrowhead Pharmaceuticals (ARWR), Ionis Pharmaceuticals (IONS), Regeneron (REGN), Bristol Myers Squibb (BMY). The cockpit's measured peer set (industry) also includes Hunan Warrant Pharmaceutical (688799.SS), Northeast Pharmaceutical (000597.SZ), Immatics (IMTX), Nxera Pharma (4565.T), GuangYuYuan Chinese Herbal Medicine (600771.SS), Dezhan Healthcare (000813.SZ).